Product Description
ERBB2 inhibitor TQB-2102 is an antibody-drug conjugate (ADC) that works by selectively targeting and inhibiting the activity of the ERBB2 receptor, which is overexpressed in certain types of cancer cells. TQB-2102 is designed to deliver a toxic payload directly to cancer cells while minimizing damage to healthy cells. As an ADC, TQB-2102 consists of a monoclonal antibody that specifically binds to the ERBB2 receptor, which is linked to a potent cytotoxic agent. When TQB-2102 binds to the ERBB2 receptor on cancer cells, it is internalized into the cell where the cytotoxic agent is released and induces cell death. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05735496?term=NCT05735496&draw=2&rank=1)
Mechanisms of Action: HER2 Inhibitor
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Sino Biopharmaceutical
Company Location:
Company Founding Year: 1997
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 23
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Breast Cancer|Colorectal Cancer
Phase 2: Adenocarcinoma|Biliary Tract Cancer|Esophageal Cancer|Gastrointestinal Cancer|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified
Phase 1: Oncology Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07483684 |
TQB2102-III-03 | P3 |
Not yet recruiting |
Colorectal Cancer |
2027-08-01 |
22% |
2026-03-20 |
Primary Endpoints |
NCT06561607 |
TQB2102-III-01 | P3 |
Active, not recruiting |
Breast Cancer |
2027-01-01 |
20% |
2026-09-11 |
Primary Endpoints|Start Date |
NCT06431490 |
TQB2102-Ib/II-01 | P2 |
Recruiting |
Biliary Tract Cancer |
2027-05-01 |
12% |
2026-04-09 |
Patient Enrollment|Primary Endpoints |
NCT06767800 |
TQB2102-II-04 | P2 |
Recruiting |
Esophageal Cancer|Gastrointestinal Cancer|Adenocarcinoma |
2026-09-01 |
2025-07-31 |
Patient Enrollment|Primary Endpoints|Start Date|Treatments|Trial Status |
|
NCT06496490 |
TQB2102-II-03 | P2 |
Recruiting |
Non-Small-Cell Lung Cancer |
2026-06-01 |
2025-11-21 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT06798207 |
TQB2102-II-05 | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2026-05-01 |
2025-07-19 |
Patient Enrollment|Primary Endpoints|Treatments |
|
NCT05735496 |
TQB2102-I-01 | P1 |
Active, not recruiting |
Oncology Unspecified |
2025-07-21 |
2025-08-05 |
Primary Endpoints |
|
NCT06198751 |
TQB2102-II-01 | P2 |
Active, not recruiting |
Breast Cancer |
2025-05-08 |
2025-08-20 |
||
CTR20243929 |
CTR20243929 | P2 |
Recruiting |
Adenocarcinoma|Gastrointestinal Cancer|Esophageal Cancer |
None |
2025-08-13 |
Patient Enrollment|Treatments |
|
CTR20240986 |
CTR20240986 | P2 |
Recruiting |
Breast Cancer |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
CTR20242017 |
CTR20242017 | P2 |
Recruiting |
Non-Small-Cell Lung Cancer |
None |
2025-10-28 |
Patient Enrollment|Treatments |
|
CTR20250493 |
CTR20250493 | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
None |
2025-07-27 |
Patient Enrollment|Treatments |
|
NCT07003074 |
TQB2102-III-06 | P3 |
Recruiting |
Breast Cancer |
2029-07-01 |
2025-06-26 |
Primary Endpoints|Start Date|Treatments|Trial Status |
|
NCT07008976 |
TQB2102-III-02 | P3 |
Recruiting |
Breast Cancer |
2028-03-01 |
2025-08-15 |
Primary Endpoints|Start Date |
|
NCT07043725 |
TQB2102-III-05 | P3 |
Recruiting |
Breast Cancer |
2027-09-01 |
24% |
2025-09-24 |
Primary Endpoints|Start Date|Treatments|Trial Status |
CTR20242868 |
CTR20242868 | P3 |
Active, not recruiting |
Breast Cancer |
None |
2026-03-17 |
Patient Enrollment|Treatments|Trial Status |
|
CTR20251922 |
CTR20251922 | P3 |
Active, not recruiting |
Breast Cancer |
None |
2026-04-14 |
Patient Enrollment|Treatments|Trial Status |
|
CTR20230394 |
CTR20230394 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2026-08-21 |
2026-08-30 |
||
CTR20233430 |
CTR20233430 | P1 |
Completed |
Breast Cancer |
2026-06-24 |
2026-07-12 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT06115902 |
TQB2102-Ib-01 | P1 |
Completed |
Breast Cancer |
2025-02-01 |
2026-07-09 |
||
NCT07512583 |
TQB2930-TQB2102-Ib/II-01 | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2028-03-01 |
12% |
2026-06-10 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT06452706 |
TQB2102-II-02 | P2 |
Recruiting |
Breast Cancer |
2026-06-01 |
2024-11-20 |
Primary Endpoints|Start Date|Treatments|Trial Status |
|
CTR20234259 |
CTR20234259 | P2 |
Completed |
Breast Cancer |
2025-06-26 |
2025-07-27 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/18/2025 |
News Article |
Sino Biopharm (1177.HK) Announces 2025 Interim Results |